Skip to main content
. 2012 Dec 13;34(8):605–614. doi: 10.1093/eurheartj/ehs425

Figure 2.

Figure 2

Cumulative survival free from major adverse events in the per-protocol (A) and in the intention-to-treat (B) populations.